Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4569-4574

  Maeda, Kazunari ^a   Hazama, Shoichi ^a   Tokuno, Kazuhisa ^a   Kan, Shin ^a   Maeda, Yoshinari ^a   Watanabe, Yusaku ^a   Kamei, Ryoji ^a   Shindo, Yoshitaro ^a   Maeda, Noriko ^a   Yoshimura, Kiyoshi ^a   Yoshino, Shigefumi ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunity; Colorectal cancer; FOLFIRI; FOLFOX; Regulatory T cells

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD4 ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PEPTIDE VACCINE; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; METASTASIS; NEUTROPHIL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; LEUCOVORIN; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84855178795     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. + immunoregulatory T-cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296, 1998.
2. + regulatory T-cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192: 303-310, 2000.
3. + cells: a naturally occurring population of regulatory T-cells. Blood 98: 2736-2744, 2001.
4. high regulatory cells in human peripheral blood. J Immunol 167: 1245-1253, 2001.
5. + T-cells with regulatory properties isolated from peripheral blood. J Exp Med 193: 1285-1294, 2001.
6. + regulatory T-cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562, 2004.
7. + regulatory T-cells. Nat Immunol 4: 330-336, 2003.
8. Hori S, Nomura T and Sakaguchi S: Control of regulatory T-cell development by the transcription factor FoxP3. Science 299: 1057-1061, 2003. (Pubitemid 36222930)
9. + T-regulatory cells. Nat Immunol 4: 337-342, 2003.
10. Tokuno K, Hazama S, Yoshino S, Yoshida S and Oka M: Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res 29: 1527-1532, 2009.
11. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001.
12. Sasada T, Kimura M, Yoshida Y, Kanai M and Takabayashi A: CD4+CD25+ regulatory T-cells in patients with gastrointestinal malignancies: possible involvement of regulatory T-cells in disease progression. Cancer 98: 1089-1099, 2003. (Pubitemid 37022112)
13. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T-cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003. (Pubitemid 36182591)
14. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H: Increased populations of regulatory T-cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408, 2003. (Pubitemid 37248397)
15. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T-cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464, 2005. (Pubitemid 40490158)
16. + regulatory T-cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92: 913-920, 2005.
17. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H and Fujii H: CD4(+)CD25(high) regulatory T-cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55: 1064-1071, 2006. (Pubitemid 43800721)
18. high T-cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405, 2006.
19. Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T-cells and immune tolerance. Cell 133: 775-787, 2008.
20. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004. (Pubitemid 39273735)
21. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L and Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25(+) regulatory T-cells and restores T and NK effector functions in end-stage cancer patients. Cancer Immunol Immunother 56: 641-648, 2007. (Pubitemid 46348738)
22. hi regulatory T-cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025, 2005.
23. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, Zhang Y, Cai Y, Chu Y and Xiong S: Differential impairment of regulatory T-cells rather than effector T-cells by paclitaxel-based chemotherapy. Clin Immunol 129: 219-229, 2008.
24. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, Rotundo MS, Ginanneschi C, Martellucci I, Francini E, Cusi MG, Tassone P and Francini G: Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 14: 4192-4199, 2008.
25. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, Wassan H, Habib N and Anthoney A: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 13: 4487-4494, 2007. (Pubitemid 47219718)
26. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N and Hawkins RE: Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57: 977-986, 2008.
27. Hong SH, Yoon IH, Kim YH, Yang SH, Park MJ, Nam HY, Kim B, Kim Y, Park CS and Park CG: High-dose cyclophosphamide-mediated antitumor effects by the superior expansion of CD44(high) cells after their selective depletion. Immunobiology 215: 182-193, 2010.
28. Alvino E, Fuggetta MP, Tricarico M and Bonmassar E: 2′-2′- Difluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 18: 3597-3602, 1998. (Pubitemid 28546496)
29. Plate JM, Plate AE, Shott S, Bograd S and Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54: 915-925, 2005. (Pubitemid 40991334)
30. + regulatory T-cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116: 2423-2433, 2006.
31. Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST and Kim TG: Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 28: 7787-7796, 2010.